

GABAergic Neuron-Specific Loss of *Ube3a* Causes Angelman Syndrome-Like EEG Abnormalities and Enhances Seizure Susceptibility

Highlights

- Glutamatergic *Ube3a* loss decreases tonic inhibition onto L2/3 pyramidal neurons
- GABAergic *Ube3a* loss does not compromise inhibition onto L2/3 pyramidal neurons
- GABAergic, not glutamatergic, *Ube3a* loss causes EEG abnormalities and seizures
- L2/3 GABAergic defects in AS mice neither cause, nor are caused by, seizures

Authors

Matthew C. Judson, Michael L. Wallace, Michael S. Sidorov, ..., Ype Elgersma, Richard J. Weinberg, Benjamin D. Philpot

Correspondence

bphilpot@med.unc.edu

In Brief

Judson and colleagues use neuron-type-specific manipulations of maternal *Ube3a* expression to demonstrate that GABAergic *Ube3a* loss is sufficient to yield Angelman syndrome-like EEG abnormalities, enhancements in seizure susceptibility, and atypical clathrin-coated vesicle accumulations within presynaptic terminals.

GABAergic Neuron-Specific Loss of *Ube3a* Causes Angelman Syndrome-Like EEG Abnormalities and Enhances Seizure Susceptibility

Matthew C. Judson,^{1,3,9} Michael L. Wallace,^{2,3,8,9} Michael S. Sidorov,^{1,3} Alain C. Burette,¹ Bin Gu,^{1,3} Geeske M. van Woerden,^{4,5} Ian F. King,⁶ Ji Eun Han,¹ Mark J. Zylka,^{1,2,3,7} Ype Elgersma,^{4,5} Richard J. Weinberg,^{1,2} and Benjamin D. Philpot^{1,2,3,7,*}

¹Department of Cell Biology and Physiology

²Curriculum in Neurobiology

³Carolina Institute for Developmental Disabilities

University of North Carolina, Chapel Hill, NC 27599, USA

⁴Department of Neuroscience

⁵ENCORE Center for Neurodevelopmental Disorders

Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, the Netherlands

⁶Department of Pathology and Laboratory Medicine

⁷Neuroscience Center

University of North Carolina, Chapel Hill, Chapel Hill, NC 27599, USA

⁸Present address: Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA

⁹Co-first author

*Correspondence: bphilpot@med.unc.edu

<http://dx.doi.org/10.1016/j.neuron.2016.02.040>

SUMMARY


Loss of maternal *UBE3A* causes Angelman syndrome (AS), a neurodevelopmental disorder associated with severe epilepsy. We previously implicated GABAergic deficits onto layer (L) 2/3 pyramidal neurons in the pathogenesis of neocortical hyperexcitability, and perhaps epilepsy, in AS model mice. Here we investigate consequences of selective *Ube3a* loss from either GABAergic or glutamatergic neurons, focusing on the development of hyperexcitability within L2/3 neocortex and in broader circuit and behavioral contexts. We find that GABAergic *Ube3a* loss causes AS-like increases in neocortical EEG delta power, enhances seizure susceptibility, and leads to presynaptic accumulation of clathrin-coated vesicles (CCVs)—all without decreasing GABAergic inhibition onto L2/3 pyramidal neurons. Conversely, glutamatergic *Ube3a* loss fails to yield EEG abnormalities, seizures, or associated CCV phenotypes, despite impairing tonic inhibition onto L2/3 pyramidal neurons. These results substantiate GABAergic *Ube3a* loss as the principal cause of circuit hyperexcitability in AS mice, lending insight into ictogenic mechanisms in AS.

INTRODUCTION

Angelman syndrome (AS) is a debilitating neurodevelopmental disorder defined by severe developmental delay, movement dis-

orders, profound speech impairment, and highly penetrant electroencephalographic (EEG) abnormalities and seizures (Williams et al., 2006; Thibert et al., 2013). The frequency, severity, and intractability of the seizures exact a heavy toll on the quality of life of individuals with AS and their caregivers (Thibert et al., 2013). Loss of function of the maternal *UBE3A* allele causes AS (Kishino et al., 1997; Matsuura et al., 1997; Sutcliffe et al., 1997). *UBE3A* encodes an E3 ubiquitin ligase, which catalyzes the transfer of ubiquitin to substrate proteins, thereby targeting them for proteasomal degradation or otherwise altering their localization or function (Rotin and Kumar, 2009; Mabb and Ehlers, 2010; Mabb et al., 2011). Because mutations that selectively inhibit *UBE3A* ligase activity are sufficient to cause AS, improper ubiquitin substrate regulation likely contributes to the pathogenesis of the disorder (Cooper et al., 2004). Unlike other cells, neurons express *UBE3A* exclusively from the maternal allele due to evolutionarily conserved, cell-type-specific epigenetic mechanisms that silence the paternal *UBE3A* allele (Rougeulle et al., 1997; Yamasaki et al., 2003; Judson et al., 2014). Accordingly, neurons are especially vulnerable to loss of maternal *UBE3A*.

Previously, we utilized a maternal *Ube3a*-null (*Ube3a*^{M−/P+}) mouse model of AS (Jiang et al., 1998) to explore the neural basis of hyperexcitability phenotypes in the disorder. We discovered that severe reduction of inhibitory GABAergic input to layer (L) 2/3 pyramidal neurons outweighs corresponding losses of excitatory glutamatergic input, possibly contributing to neocortical hyperexcitability. Recovery of inhibitory synaptic transmission following high-frequency stimulation is severely compromised and is associated with accumulations of clathrin-coated vesicles (CCVs) at GABAergic presynaptic terminals onto L2/3 pyramidal neurons (Wallace et al., 2012). Maternal *Ube3a* deficiency may thus disrupt presynaptic vesicle cycling in GABAergic neurons, possibly through the dysregulation of *UBE3A* substrates that



amplitude normalized to baseline during 90 stimuli at 0.33 Hz. Each point (30 plotted per genotype) represents three consecutive responses that were collapsed and averaged per cell. Average depletion and recovery responses for each genotype were fit with a monophasic exponential (Control n = 11 cells; *Ube3a*^{FLOX/p+::Gad2-Cre} n = 9 cells). Data represent mean \pm SEM.

directly or indirectly compromise clathrin-mediated endocytosis. Conversely, it is possible that loss of maternal *Ube3a* expression in glutamatergic neurons compromises the postsynaptic effects of GABA on L2/3 pyramidal neurons, thereby contributing to hyperexcitability within the microcircuit and throughout the brain. In support of this latter possibility, modulation of expression or activity levels of ARC or the calcium/calmodulin-dependent kinase type II- α subunit (CaMKII- α)—both of which are preferentially expressed by glutamatergic forebrain neurons—has been shown to rescue circuit hyperexcitability and seizures in *Ube3a*^{m-/p+} mice (van Woerden et al., 2007; Mandel-Brehm et al., 2015). Thus, an immediate goal is to determine whether maternal *Ube3a* loss restricted to either GABAergic or glutamatergic neurons is sufficient to impair GABAergic inhibition onto L2/3 pyramidal neurons, thereby leading to broader circuit-level and behavioral manifestations of hyperexcitability.

Here we utilize novel conditional *Ube3a* mouse models to identify the neurons and neural circuits underlying the pathogenesis of circuit hyperexcitability in AS. We focus on selective *Ube3a* loss from GABAergic or glutamatergic neurons, which are largely responsible for orchestrating the balance between excitation and inhibition in cerebral circuits. Our results provide compelling evidence that GABAergic, but not glutamatergic, *Ube3a* loss is responsible for mediating the EEG abnormalities and seizures that affect individuals with AS.

Figure 1. GABAergic *Ube3a* Loss Does Not Compromise Synaptic Inhibition onto L2/3 Pyramidal Neurons

(A) Immunostaining of parvalbumin (PV), Cux1, and UBE3A in V1 of ~P80 Control (A₁) and *Ube3a*^{FLOX/p+::Gad2-Cre} (A₂) mice. Arrowheads indicate PV-positive interneurons, which lack UBE3A in *Ube3a*^{FLOX/p+::Gad2-Cre} mice (scale bar: 145 μ m or 75 μ m for zoom-ins).

(B) Schematic for recording synaptic inhibition onto L2/3 pyramidal neurons in V1 of ~P80 *Ube3a*^{FLOX/p+::Gad2-Cre} mice (green shading indicates presence of UBE3A).

(C) Sample recordings (scale bar: 20 pA, 200 ms) and quantification of mIPSC amplitude and frequency (Control n = 11 cells; *Ube3a*^{FLOX/p+::Gad2-Cre n = 17 cells).}

(D) Sample recordings of eIPSCs (D₁) at stimulation intensities of 2, 10, 30, and 100 μ A (scale bar: 1 nA, 40 ms). (D₂) Quantification of eIPSCs. Inset depicts response amplitudes to 100 μ A stimulation (Control n = 22 cells; *Ube3a*^{FLOX/p+::Gad2-Cre n = 24 cells).}

(E) Sample recordings (E₁) depicting each phase of an inhibitory synaptic depletion and recovery experiment (scale bars: baseline = 200 pA, 20 ms; depletion = 200 pA, 70 ms; recovery = 200 pA, 20 ms). (E₂) Average depletion phase showing eIPSC amplitude normalized to baseline during 800 stimuli at 30 Hz. Each point (80 plotted per genotype) represents ten consecutive responses that were collapsed and averaged per cell. (E₃) Average recovery phase showing eIPSC amplitude normalized to baseline during 90 stimuli at 0.33 Hz. Each point (30 plotted per genotype) represents three consecutive responses that were collapsed and averaged per cell.

RESULTS

GABAergic *Ube3a* Loss Does Not Impair GABAergic Neurotransmission onto L2/3 Pyramidal Neurons

To enable genetic dissection of neuron-type-specific contributions to circuit hyperexcitability in AS, we generated a novel mouse with maternal inheritance of a floxed *Ube3a* allele (*Ube3a*^{FLOX/p+}) (Figure S1). We first crossed *Ube3a*^{FLOX/p+} mice to a *Gad2-Cre* line in which Cre is expressed by almost all inhibitory GABAergic neurons throughout the brain (Taniguchi et al., 2011). We immunohistochemically confirmed loss of UBE3A expression by GABAergic interneurons in adult *Ube3a*^{FLOX/p+::Gad2-Cre} mice, including parvalbumin-expressing subtypes in primary visual cortex (V1) (Figure 1A₂). The density of these interneuron subtypes in V1 was normal (Figure S2A), indicating that GABAergic *Ube3a* loss does not grossly disrupt GABAergic neuronal architecture in the neocortex. Moreover, GABAergic *Ube3a* loss in *Ube3a*^{FLOX/p+::Gad2-Cre} mice proved to be selective, as UBE3A co-staining with the L2–4 glutamatergic neuron marker, Cux1 (Nieto et al., 2004), was intact (Figures 1A₁ and 1A₂).

We then sought to determine if GABAergic neuron-specific loss of maternal *Ube3a* is sufficient to alter synaptic drive onto L2/3 pyramidal neurons, testing *Ube3a*^{FLOX/p+::Gad2-Cre} mice for the same spectrum of synaptic defects that we had previously observed in V1 of AS model mice (*Ube3a*^{m-/p+})

(Wallace et al., 2012). As expected, we found no difference in mEPSC amplitude or frequency onto L2/3 pyramidal neurons in *Ube3a*^{FLOX/p+::Gad2-Cre} compared to *Control* mice (Figure S2B). We also observed normal mIPSC amplitude and frequency in *Ube3a*^{FLOX/p+::Gad2-Cre} mice (Figure 1C), indicating that spontaneous GABAergic synaptic transmission remains intact following GABAergic neuron-specific loss of maternal *Ube3a*. This was unexpected, in view of previous evidence that decreased mIPSC frequency is a core GABAergic synaptic defect onto L2/3 pyramidal neurons in *Ube3a*^{m-/p+} mice (Table 1) (Wallace et al., 2012).

We were even more surprised to find that GABAergic *Ube3a* loss yields neither of two core deficits in electrically evoked inhibition observed in *Ube3a*^{m-/p+} mice: decreased evoked inhibitory postsynaptic current (eIPSC) amplitude or blunted recovery of GABAergic synaptic responses following high-frequency stimulation (Table 1). By stimulating (150 µm inferior to the recorded neuron) at a range of intensities, we revealed that eIPSC response amplitudes in *Ube3a*^{FLOX/p+::Gad2-Cre} mice are equivalent to *Control* (Figure 1D), indicating that the strength of GABAergic inputs onto L2/3 pyramidal neurons develops normally following GABAergic *Ube3a* loss. To test the recovery of GABAergic synaptic transmission following high-frequency stimulation, we applied a train of 800 stimuli at 30 Hz to deplete reserves of GABAergic vesicles, followed immediately by 0.33 Hz stimulation to allow for recovery (Figure 1E1). We recorded eIPSC amplitudes from L2/3 pyramidal neurons during both phases of this experiment, to gauge rates of GABAergic synaptic depletion and recovery. Depletion of eIPSC amplitude in *Ube3a*^{FLOX/p+::Gad2-Cre} mice was equivalent to *Control* (Figure 1E2), as was recovery (Figure 1E3). Although eIPSC paired-pulse ratio in *Ube3a*^{FLOX/p+::Gad2-Cre} mice was subtly decreased when stimulating with a 100 ms inter-stimulus interval (ISI), eIPSC paired-pulse with 33 ms ISI was normal (Figure S2C). Thus, short-term plasticity at this synapse is largely intact following GABAergic *Ube3a* loss, particularly in response to the stimulation frequency we used to deplete GABAergic synapses (Figure 1E₂).

Importantly, nervous system-wide deletion of *Ube3a*^{FLOX/p+} (*Ube3a*^{FLOX/p+::Nestin-Cre}) produced a loss of *Ube3a* expression that was indistinguishable from *Ube3a* loss in *Ube3a*^{m-/p+} mice (Figure S3); moreover, *Ube3a*^{FLOX/p+::Nestin-Cre} mice closely phenocopied L2/3 GABAergic synaptic defects in *Ube3a*^{m-/p+} mice (Table 1; Figure S4). *Ube3a*^{FLOX} thus appears to be a viable conditional null allele, supporting the lack of phenotypic penetrance in *Ube3a*^{FLOX/p+::Gad2-Cre} mice as a genuine finding, rather than an artifact of residual *Ube3a* function following *Gad2-Cre*-mediated deletion. Collectively, these observations indicate that GABAergic *Ube3a* loss does not severely impair GABAergic synaptic drive onto L2/3 pyramidal neurons as results from *Ube3a* loss in all neurons (Table 1).

Glutamatergic *Ube3a* Loss Impairs Electrically Evoked and Tonic GABAergic Inhibition onto L2/3 Pyramidal Neurons

To model glutamatergic *Ube3a* loss in a manner truly reciprocal to GABAergic *Ube3a* loss in *Ube3a*^{FLOX/p+::Gad2-Cre} mice, we crossed conditional *Ube3a* reinstatement mice (*Ube3a*^{STOP/p+})

to the same *Gad2-Cre* line. *Ube3a*^{STOP/p+} mice constitute a conditional AS model in which expression of the maternal *Ube3a* allele is interrupted by targeted insertion of a floxed STOP cassette. Cre-mediated excision of the STOP cassette fully reinstates neuronal UBE3A expression in *Ube3a*^{STOP/p+} mice (Silva-Santos et al., 2015). Hence, when we crossed *Ube3a*^{STOP/p+} mice to *Gad2-Cre* mice (*Ube3a*^{STOP/p+::Gad2-Cre}), we observed UBE3A reinstatement that was specific to GABAergic interneurons in the neocortex, leaving neighboring Cux1-expressing glutamatergic neurons devoid of UBE3A expression in L2/3 neocortex (Figure 2A). Thus, *Ube3a*^{STOP/p+::Gad2-Cre} mice are an appropriate model of glutamatergic *Ube3a* loss.

To evaluate whether glutamatergic *Ube3a* loss in *Ube3a*^{STOP/p+::Gad2-Cre} mice could impair GABAergic synaptic drive onto L2/3 pyramidal neurons, we first needed to determine the extent to which *Ube3a*^{STOP/p+} mice recapitulated key GABAergic synaptic defects. We found that *Ube3a*^{STOP/p+} mice closely phenocopied *Ube3a*^{m-/p+} and *Ube3a*^{FLOX/p+::Nestin-Cre} mice with respect to reduced eIPSC amplitude (Figure 2C) and blunted recovery from inhibitory synaptic depletion (Figure 2D). However, *Ube3a*^{STOP/p+} mice failed to exhibit mIPSC amplitude or frequency deficits despite our experimentation with near-physiological as well as increased intracellular chloride levels (Figures S5B and S5C). It is possible that *Ube3a*^{STOP} allele readthrough provided enough *Ube3a* expression, albeit very low (Silva-Santos et al., 2015), to selectively mitigate penetrance of the mIPSC deficit. Regardless of the underlying reason for this result, we were limited to evaluating only eIPSC amplitude and GABAergic synaptic recovery in *Ube3a*^{STOP/p+::Gad2-Cre} mice.

Ube3a^{STOP/p+::Gad2-Cre} mice proved to be statistically indistinguishable from *Ube3a*^{STOP/p+} (but also *Control*) mice on measures of eIPSC amplitude (Figure 2C), providing a clue that glutamatergic *Ube3a* loss diminishes L2/3 pyramidal neuron responses to evoked GABAergic neurotransmission. Similar to *Ube3a*^{STOP/p+} and *Control* mice, *Ube3a*^{STOP/p+::Gad2-Cre} mice showed no impairment on measures of mEPSCs, eIPSC paired-pulse ratios, or inhibitory synaptic depletion dynamics (Figures S5A, S5D, S5E₁, and S5E₂). In contrast, the blunted recovery from GABAergic synaptic depletion that we observed in *Ube3a*^{STOP/p+} mice was completely absent in *Ube3a*^{STOP/p+::Gad2-Cre} mice (Figure 2D). This result demonstrates that glutamatergic *Ube3a* loss, just like GABAergic *Ube3a* loss (Figure 1E), fails to impair GABAergic synaptic recovery from high-frequency stimulation.

Selective manipulations of glutamatergic *Ube3a* expression in the neocortex should affect the penetrance of eIPSC amplitude deficits, assuming these deficits are secondary to an intrinsic loss of UBE3A function within L2/3 pyramidal neurons. We tested this assumption with several approaches. First, we crossed *Ube3a*^{STOP/p+} mice to a NEX-Cre line (*Ube3a*^{STOP/p+::NEX-Cre}) in which *Ube3a* is selectively reinstated in glutamatergic neurons of the dorsal pallium, including Cux1-positive neurons of L2/3 neocortex (Figure 3A₃). eIPSC amplitudes in *Ube3a*^{STOP/p+::NEX-Cre} mice were similar to *Control* (Figures 3B and 3C), supporting that this deficit in *Ube3a*^{STOP/p+} mice is driven by glutamatergic, not GABAergic, *Ube3a* loss in L2/3 neocortex, in agreement with our findings from *Ube3a*^{FLOX/p+::Gad2-Cre mice (Figure 1D). To further demonstrate the neuron}

Table 1. Summary of Neocortical Inhibitory Synaptic Defects, EEG Abnormalities, and Behavioral Seizure Phenotypes in *Ube3a* Mice

Mouse Model	UBE3A Expression Deficit	GABAergic Synaptic Defects onto L2/3 Pyramidal Neurons					Behavioral Seizure Phenotype
		mIPSC Freq.	Inhibitory eIPSC Amp.	Inhibitory Synaptic Recovery	Presynaptic CCVs	Intracortical EEG	
<i>Ube3a</i> ^{m−/p+}	deleted in all neurons	↓49% ^a	↓43% ^a	↓30% ^a	↑214% ^a	electrographic seizures, polyspike and slow wave discharges ^b	spontaneous: yes ^b ; flurothyl: NA; AGS: enhanced susceptibility ^{b,c}
<i>Ube3a</i> ^{FLOX/p+::Nestin-Cre}	deleted in all neurons	↓25%	↓18%	↓18%	↑124%	NA	NA
<i>Ube3a</i> ^{STOP/p+::Gad2-Cre}	suppressed in all neurons	↔	↓20%	↓32%	↑222%	enhanced delta power	spontaneous: not observed; flurothyl: NA; AGS: enhanced susceptibility ^d
<i>Ube3a</i> ^{FLOX/p+::Gad2-Cre}	deleted in nearly all GABAergic neurons	↔	↔	↔	↑116%	enhanced delta power	spontaneous: yes, enhanced postnatal lethality; flurothyl: decreased latency, enhanced lethality; AGS: enhanced susceptibility, severe
<i>Ube3a</i> ^{STOP/p+::Gad2-Cre}	suppressed in all glutamatergic neurons and other non-GABAergic neurons	↔	↓10% ^e	↔	↔	normal spectral power	spontaneous: not observed; flurothyl: NA; AGS: not susceptible
<i>Ube3a</i> ^{FLOX/p+::NEX-Cre}	deleted in glutamatergic neurons of dorsal pallial origin	↔	↓25%	↔	NA	NA	spontaneous: not observed; flurothyl: normal susceptibility; AGS: NA

↔, equivalent to Control; ↑, increased relative to Control; ↓, decreased relative to Control; NA, Not Assayed; AGS, audiogenic seizure.

^aWallace et al. (2012).

^bJiang et al. (1998).

^cvan Woerden et al. (2007).

^dSilva-Santos et al. (2015).

^eDid not reach statistical significance.




Figure 2. GABAergic *Ube3a* Reinstatement in *Ube3a*^{STOP/p+::Gad2-Cre} Mice Models Glutamatergic *Ube3a* Loss and Indicates an Evoked IPSC Amplitude Deficit onto L2/3 Pyramidal Neurons

(A) Immunostaining of parvalbumin (PV), Cux1, and UBE3A in V1 of ~P80 Control (A₁); *Ube3a*^{STOP/p+} (A₂); and *Ube3a*^{STOP/p+::Gad2-Cre} (A₃) mice. Arrowheads indicate PV-positive interneurons that co-stain for UBE3A. Arrows point to PV-negative interneurons that co-stain for UBE3A (scale bar: 145 μm or 75 μm for zoom-ins).

(B) Schematic for recording synaptic inhibition onto L2/3 pyramidal neurons in V1 of ~P80 *Ube3a*^{STOP/p+::Gad2-Cre} mice.

(C) Sample recordings of eIPSCs (C₁) at stimulation intensities of 2, 10, 30, and 100 μA (scale bar: 1 nA, 60 ms). (C₂) Quantification of eIPSCs. Inset depicts response amplitudes to 100 μA stimulation (Control n = 38 cells; *Ube3a*^{STOP/p+} n = 44 cells; *Ube3a*^{STOP/p+::Gad2-Cre} n = 40 cells).

(D) Inhibitory synaptic depletion and recovery in Control (n = 9 cells), *Ube3a*^{STOP/p+} (n = 11 cells), and *Ube3a*^{STOP/p+::Gad2-Cre} (n = 13 cells) mice, performed as in Figure 1E. Scale bars (D₁): baseline = 200 pA, 20 ms; depletion = 200 pA, 70 ms; recovery = 200 pA, 20 ms. Data represent mean ± SEM. *p ≤ 0.05.


type specificity of this phenotype, we probed *Ube3a*^{FLOX/p+::NEX-Cre} mice (Figure 3A₄), observing that neocortical glutamatergic *Ube3a* deletion was sufficient to yield the eIPSC deficit (Figures 3D and 3E). Finally, to test the cell autonomy of the effect, we intracerebroventricularly delivered low titers of Cre-expressing adeno-associated virus (AAV-Cre) to neonatal *Ube3a*^{FLOX/p+} and *Ube3a*^{m+/p+} control littermates (Figure S6A₁). This produced a sparse mosaic of virally transduced neocortical neurons, including pyramidal neurons, which we identified by expression of a Cre-dependent tdTomato reporter. We observed a total loss of UBE3A expression in over 80% of tdTomato-positive neurons in *Ube3a*^{FLOX/p+} mice by P12 (Figures S6A₃ and S6A₄). Conversely, almost all (>90%) tdTomato-positive neurons expressed UBE3A in *Ube3a*^{m+/p+} littermates (Figures S6A₂ and S6A₄). We measured eIPSC amplitude in mice prepared in this manner at ~P80, recording from tdTomato-positive L2/3 pyramidal neurons (*Ube3a*^{FLOX/p+::AAV-Cre} or *Ube3a*^{m+/p+::AAV-Cre}), as well as neighboring non-transduced L2/3 pyramidal neurons (*Ube3a*^{FLOX/p+} or *Ube3a*^{m+/p+}) in V1 (Figure S6B₁). We observed reduced eIPSC amplitude in response to a range of stimulation intensities in *Ube3a*^{FLOX/p+::AAV-Cre} neurons compared to *Ube3a*^{m+/p+::AAV-Cre}, *Ube3a*^{FLOX/p+}, or *Ube3a*^{m+/p+} neurons (Figure S6B₂ and S6B₃). We therefore conclude that diminished eIPSC amplitude onto L2/3 pyramidal neurons in AS mice is due to cell-autonomous consequences of *Ube3a* loss.

Intriguingly, deficits in eIPSC amplitude in *Ube3a*^{FLOX/p+::NEX-Cre} mice occurred in the absence of changes in either mIPSC amplitude or frequency (Figure 3F), indicating that synaptic GABA_AR function may be normal following glutamatergic

Ube3a deletion in the dorsal forebrain. This apparent phenotypic discrepancy may be explained by deficits in extrasynaptic, delta subunit-containing GABA_ARs (δ-GABA_ARs), which might only be revealed in instances of GABA spillover to extrasynaptic regions (for example, following strong electrical stimulation) (Wei et al., 2003). Because δ-GABA_ARs are the principal mediators of tonic inhibition onto pyramidal neurons in the neocortex (Brickley and Mody, 2012), we reasoned that glutamatergic *Ube3a* loss might selectively impair this mode of GABAergic transmission by L2/3 pyramidal neurons. To test this, we bath-applied a δ-GABA_AR-selective concentration of THIP (Gaboxadol) to stimulate extrasynaptic GABA_ARs, followed by a saturating concentration of the competitive GABA_AR antagonist, Gabazine (SR95531) (Figure 3G1). We recorded corresponding changes in holding current in L2/3 pyramidal neurons, finding that we could stimulate significantly less THIP/Gabazine-sensitive tonic current in *Ube3a*^{FLOX/p+::NEX-Cre} mice relative to Control (Figure 3G2). This effect was not an artifact of decreased cell size, as capacitances between the two genotypes were equivalent (Control n = 30 cells, 64.06 ± 3 pF; *Ube3a*^{FLOX/p+::NEX-Cre} n = 21 cells, 68.33 ± 4.71 pF; p = 0.43). Together, these observations support that glutamatergic *Ube3a* loss cell-autonomously impairs tonic GABAergic tone onto L2/3 pyramidal neurons.

GABAergic, but Not Glutamatergic, *Ube3a* Loss Enhances Seizure Susceptibility

Converging lines of evidence implicate deficits in tonic inhibition in the pathogenesis of epilepsy. In particular, *GABRD* missense mutations that reduce δ-GABA_AR-mediated currents



pyramidal neurons (scale bar: 150 pA, 120 s). (G₂) Quantification of change in $I_{holding}$ in response to the application of the δ -GABA_AR agonist THIP (left) and the subsequent chase with the competitive GABA_AR antagonist, Gabazine (right) (Control n = 30 cells; Ube3a^{FLOX/p+::NEX-Cre} n = 21 cells). Data represent mean \pm SEM. *p \leq 0.05, **p \leq 0.01.

are associated with generalized epilepsy in humans (Dibbens et al., 2004), and *Gabrd*^{-/-} mice are prone to seizures (Spigelman et al., 2002; Maguire et al., 2005). Therefore, we hypothesized that deficits owed to glutamatergic *Ube3a* loss, including impaired tonic δ -GABA_AR-mediated inhibition onto pyramidal neurons, would correlate with enhanced seizure susceptibility.

Latencies to seizure following an initial exposure to the putative GABA_AR antagonist, flurothyl, provide a reliable index of seizure threshold in naive mice, and flurothyl seizures are highly penetrant regardless of genetic background (Krasowski, 2000; Kadiyala et al., 2014). We therefore used flurothyl to test seizure susceptibility in congenic C57BL/6 *Ube3a*^{FLOX/p+::NEX-Cre} mice (Figures 4A₁ and 4B). Surprisingly, we found that their latency to myoclonic and generalized seizure was similar to *Control* (Figure 4C). This finding indicates that decreased tonic GABAergic inhibition onto L2/3 pyramidal neurons does not confer vulnerability to seizures. Nor, in all likelihood, does any other physiological consequence of glutamatergic *Ube3a* loss in the dorsal telencephalon. In contrast, pan-cerebral GABAergic *Ube3a* loss on a congenic C57BL/6 background yielded a dramatic reduction in latency to myoclonus and generalized seizure, and even enhanced lethality to repeated (once daily) exposures to

Figure 3. Glutamatergic *Ube3a* Loss Selectively Reduces Evoked IPSC Amplitude and Tonic Inhibitory Tone onto L2/3 Pyramidal Neurons

(A) Immunostaining of parvalbumin (PV), Cux1, and UBE3A in V1 of ~P80 *Control* (A₁); *Ube3a*^{STOP/p+} (A₂); *Ube3a*^{STOP/p+::NEX-Cre} (A₃); and *Ube3a*^{FLOX/p+::NEX-Cre} (A₄) mice. Double arrows indicate PV-positive interneurons that lack UBE3A, arrowheads indicate PV-positive interneurons that co-stain for UBE3A but lack Cux1, and single arrows depict Cux1- and PV-negative interneurons that co-stain for UBE3A (scale bar: 75 μ m for all panels).

(B) Schematic for recording inhibition onto L2/3 pyramidal neurons in V1 of ~P80 *Ube3a*^{STOP/p+::NEX-Cre} mice.

(C) Sample recordings of eIPSCs (C₁) at stimulation intensities of 2, 10, 30, and 100 μ A (scale bar: 800 pA, 20 ms). (C₂) Quantification of eIPSCs. Inset depicts response amplitudes to 100 μ A stimulation (Control n = 14 cells; *Ube3a*^{STOP/p+} n = 15 cells; *Ube3a*^{STOP/p+::NEX-Cre} n = 16 cells).

(D) Schematic for recording inhibition onto L2/3 pyramidal neurons in V1 of ~P80 *Ube3a*^{FLOX/p+::NEX-Cre} mice.

(E) Sample recordings of eIPSCs (E₁) at stimulation intensities of 2, 10, 30, and 100 μ A (scale bar: 1 nA, 40 ms). (E₂) Quantification of eIPSCs. Inset depicts response amplitudes to 80 μ A stimulation (Control n = 14 cells; *Ube3a*^{FLOX/p+::NEX-Cre} n = 22 cells).

(F) Sample recordings (F₁, scale bar: 20 pA, 200 ms) and quantification of mIPSC amplitude and frequency (F₂) (Control n = 15 cells; *Ube3a*^{FLOX/p+::NEX-Cre} n = 11 cells).

(G) Representative trace (G₁) from experiments to measure tonic inhibitory currents onto L2/3

flurothyl, as evinced by experiments in *Ube3a*^{FLOX/p+::Gad2-Cre} mice (Figures 4A₂ and 4D).

Notably, NEX-Cre does not mediate glutamatergic *Ube3a* deletion in ventral neuron populations, nor in the majority of dentate granule neurons (Figure 4A₁) (Goebels et al., 2006). Dentate granule neurons in particular receive an abundance of tonic GABAergic inhibition and are critical for gating temporal lobe excitability (Coulter and Carlson, 2007; Hsu, 2007; Pun et al., 2012), which might explain why *Ube3a*^{FLOX/p+::NEX-Cre} mice exhibit a normal response to flurothyl (Figure 4C). In contrast, *Ube3a*^{STOP/p+::Gad2-Cre} mice effectively model pan-cerebral glutamatergic *Ube3a* loss and thus provide a better model in which to fully evaluate the potential for glutamatergic *Ube3a* loss to enhance seizure susceptibility. As we maintain congenic 129S2/SvPasCrl *Ube3a*^{STOP/p+} mice, we turned to a sensory-evoked, audiogenic seizure induction paradigm that is suited to assessing seizure susceptibility on this genetic background (Figure 5A). Importantly, the audiogenic seizure paradigm has previously been used to demonstrate enhanced seizure susceptibility in AS mouse models on a 129 background, including *Ube3a*^{m-/p+} and *Ube3a*^{STOP/p+} mice (Jiang et al., 1998; van Woerden et al., 2007; Silva-Santos et al., 2015).




Figure 4. GABAergic, but Not Glutamatergic, *Ube3a* Loss Lowers the Threshold for Flurothyl-Induced Seizures

(A) UBE3A staining in *Ube3a*^{FLXO/p+::NEX-Cre} (**A₁**) and *Ube3a*^{FLXO/p+::Gad2-Cre} (**A₂**) (scale bar: 750 μ m; 400 μ m for zoom-ins). Ctx, cerebral cortex; Hip, hippocampus; MGN, medial geniculate thalamic nucleus; SNR, substantia nigra pars reticulata.

(B) Schematic of flurothyl-induced seizure protocol. Flurothyl administration ceases upon the occurrence of a generalized seizure.

(C) Latency to myoclonus (**C₁**) and generalized seizure (**C₂**) in *Control* ($n = 12$) and *Ube3a*^{FLXO/p+::NEX-Cre} ($n = 7$) mice at \sim P80.

(D) Latency to myoclonus (**D₁**) and generalized seizure (**D₂**) in *Control* ($n = 13$) and *Ube3a*^{FLXO/p+::Gad2-Cre} ($n = 11$) mice at \sim P80. Comparative survival (**D₃**) of *Control* and *Ube3a*^{FLXO/p+::Gad2-Cre} mice following repeated once daily exposures to flurothyl. Data represent mean \pm SEM. ***p \leq 0.0001.

We confirmed that 129S2/SvPasCrl *Ube3a*^{STOP/p+} mice are much more susceptible to audiogenic seizures than their *Control* littermates in terms of both frequency and severity (Figure 5B). *Ube3a*^{STOP/p+::Gad2-Cre} littermates, on the other hand, proved to be refractory to audiogenic seizure induction, similar to *Control* (Figure 5B).

In contrast, consistent with our flurothyl-induced seizure results, we found that 129S2/SvPasCrl *Ube3a*^{FLXO/p+::Gad2-Cre} mice exhibit audiogenic seizures much more frequently than *Control* littermates and with a far greater likelihood of progressing from wild running to a severe, tonic-clonic episode (Figure 5C). Surprisingly, post-weaning lethality approached 15% in *Ube3a*^{FLXO/p+::Gad2-Cre} mice and was associated with observations of spontaneous seizures (Figure 5D), whereas we observed no evidence of postnatal lethality associated with spontaneous seizures in *Ube3a*^{STOP/p+} mice. Collectively, these findings provide compelling evidence that GABAergic, but not glutamatergic, *Ube3a* loss enhances seizure susceptibility. Notably, seizures due to GABAergic *Ube3a* loss alone are more severe than those observed in AS mice with loss of *Ube3a* in both GABAergic and glutamatergic neurons (Table 1).

GABAergic, but Not Glutamatergic, *Ube3a* Loss Mediates AS-like EEG Abnormalities

If GABAergic *Ube3a* loss drives seizure susceptibility in AS, then it might also underlie AS-like EEG abnormalities, including rhythmic, high-amplitude activity in the delta and theta bands (Thibert et al., 2013). To investigate this possibility, we recorded resting-state local field potentials (LFPs) (analogous to intracortical EEG) (Buzsáki et al., 2012) in awake head-fixed mice viewing a gray screen to which they were previously habituated (Figure 6A). We observed a strong trend toward total spectral power being increased in *Ube3a*^{FLXO/p+::Gad2-Cre} mice relative to *Control* (1–50 Hz power in μ V²: *Control* = $3,195 \pm 485.8$; *Ube3a*^{FLXO/p+::Gad2-Cre} = $4,292 \pm 293.5$; p = 0.07), primarily driven by enhancements in the delta band (Figure 6B). Increased power in other bands including theta (5–10 Hz power in μ V²: *Control* = 755 ± 101.2 ; *Ube3a*^{FLXO/p+::Gad2-Cre} = 873 ± 46.8 ; p = 0.3) and gamma (30–50 Hz power in μ V²: *Control* = 90 ± 9.8 ; *Ube3a*^{FLXO/p+::Gad2-Cre} = 101 ± 6 ; p = 0.37) did not reach statistical significance. Total neocortical power was similarly elevated in *Ube3a*^{STOP/p+} mice (Figure 6C), again largely through delta, with marginal power enhancement in other bands. However, LFP power in *Ube3a*^{STOP/p+::Gad2-Cre} mice, which model glutamatergic *Ube3a* loss, was normal (Figure 6C); total (1–50 Hz power in μ V²: *Control* = $3,067 \pm 252.7$; *Ube3a*^{STOP/p+} = $4,255 \pm 529.4$; *Ube3a*^{STOP/p+::Gad2-Cre} = $2,755 \pm 391.5$; p = 0.03), theta (5–10 Hz power in μ V²: *Control* = 733 ± 53.8 ; *Ube3a*^{STOP/p+} = 879 ± 68.1 ; *Ube3a*^{STOP/p+::Gad2-Cre} = 647 ± 92.5 ; p = 0.11) and gamma (30–50 Hz power in μ V²: *Control* = 105 ± 10.7 ; *Ube3a*^{STOP/p+} = 127 ± 13.4 ; *Ube3a*^{STOP/p+::Gad2-Cre} = 91 ± 13.3 ; p = 0.16) power was equivalent between *Control* and *Ube3a*^{STOP/p+::Gad2-Cre} mice. We therefore conclude that GABAergic, but not glutamatergic, *Ube3a* loss yields AS-like enhancements in EEG delta power (Table 1).

GABAergic *Ube3a* Loss Phenocopies Presynaptic CCV Accumulations in AS Mice

We previously linked deficits in inhibitory synaptic recovery in *Ube3a*^{STOP/p+} mice to an aberrant accumulation of CCVs at GABAergic synapses (Wallace et al., 2012). This correlation suggests that maternal *Ube3a* loss may cause defective vesicle cycling, which fails to adequately restore presynaptic vesicle




Figure 5. GABAergic, but Not Glutamatergic, *Ube3a* Loss Enhances Audiogenic Seizure Susceptibility in AS Model Mice

(A) Schematic of audiogenic seizure protocol.

(B) Quantification of audiogenic seizure susceptibility in *Control* ($n = 26$), *Ube3a*^{STOP/p+} ($n = 13$), and *Ube3a*^{STOP/p+::Gad2-Cre} ($n = 13$) mice at $\sim P80$.

(C) Quantification of audiogenic seizure susceptibility (*Control* $n = 15$; *Ube3a*^{FLOX/p+::Gad2-Cre} $n = 13$).

(D) Post-weaning (P21–P90) lethality in *Control* and *Ube3a*^{FLOX/p+::Gad2-Cre} mice. Data represent mean \pm SEM. ** $p \leq 0.01$; *** $p \leq 0.001$; **** $p \leq 0.0001$.

pools following bouts of high-frequency release (Cremona et al., 1999; Luthi et al., 2001; Milosevic et al., 2011). However, GABAergic synaptic depletion is normal in *Ube3a*^{FLOX/p+::Gad2-Cre} mice (Figure 1E), leading us to question whether GABAergic *Ube3a* loss would lead to aberrant presynaptic CCVs. First, we verified that pan-cerebral deletion of the maternal *Ube3a*^{FLOX} allele results in the CCV phenotype, finding that CCVs were increased at dendritic and somatic GABAergic synapses in *Ube3a*^{FLOX/p+::Nestin-Cre} mice compared to *Control* (Figures S7A–S7C). We also found that CCVs accumulate at glutamatergic synapses in these mice (Figures S7A and S7D), a departure from what we had previously observed in *Ube3a*^{m−/p+} mice, where CCV increases at glutamatergic synapses did not reach statistical significance (Table 1). Next, we tested the effect of GABAergic *Ube3a* deletion on the CCV phenotype, comparing *Ube3a*^{FLOX/p+::Gad2-Cre} mice with littermate *Controls*. *Ube3a*^{FLOX/p+::Gad2-Cre} mice did in fact exhibit excessive CCVs at GABAergic presynaptic terminals that synapsed onto the dendrites (Figure 7A₃) and somata (Figure 7A₄) of glutamatergic neurons in L2/3. Furthermore, we observed excessive CCVs at asymmetric glutamatergic synapses made onto dendritic spines in L2/3 (Figure 7A₅). Other presynaptic measures including terminal area (Figures S8A1, S8B1, and S8C1), mitochondrial area (Figures S8A2, S8B2, and S8C2), and the density of synaptic vesicles (Figures S8A3, S8B3, and S8C3) were largely normal. Thus, GABAergic *Ube3a* loss phenocopies the presynaptic CCV abnormalities in AS mice, despite leaving recovery from GABAergic synaptic depletion intact (Figure 1E).

Excessive CCV accumulation also proved to be a feature of both GABAergic and glutamatergic L2/3 synapses in *Ube3a*^{STOP/p+} mice (Figure 7B). To determine if glutamatergic *Ube3a* loss would affect presynaptic CCVs, we compared

Ube3a^{STOP/p+::Gad2-Cre} mice to both *Ube3a*^{STOP/p+} and *Control* littermates. We found that *Ube3a*^{STOP/p+::Gad2-Cre} and *Control* mice were statistically equivalent on measures of CCV density at GABAergic and glutamatergic L2/3 synapses (Figure 7B), indicating that glutamatergic *Ube3a* loss does not contribute to this phenotype in AS mice. Presynaptic

measures of terminal area, mitochondrial area, and synaptic vesicle density were similar across the three genotypic groups (Figures S8D–S8F). Importantly, glutamatergic CCV accumulations in *Ube3a*^{STOP/p+} mice occurred in the absence of deficits in glutamatergic synaptic depletion (Figure S5E), providing yet another example of phenotypic dissociation between presynaptic CCVs and the capacity for recovery from synaptic depletion.

DISCUSSION

This work constitutes the first investigation of neuron-type-specific contributions to the pathogenesis of circuit hyperexcitability in AS. We show that GABAergic *Ube3a* deletion produces AS-like enhancements in EEG delta power, enhances seizure susceptibility and severity, and results in aberrant L2/3 presynaptic CCV accumulations. In contrast, glutamatergic *Ube3a* loss impairs the receipt of tonic GABAergic inhibition by L2/3 pyramidal neurons but does not lead to EEG abnormalities or confer vulnerability to seizures.

Our present results demonstrate that GABAergic *Ube3a* loss leads to EEG abnormalities and seizures without producing any of the defects in GABAergic inhibition that we previously observed in L2/3 neocortex in AS mice, which lack *Ube3a* in nearly all neurons (Wallace et al., 2012). The immediate implication of this surprising finding is that defective GABAergic inhibition onto L2/3 pyramidal neurons is neither a cause nor a consequence of circuit hyperexcitability in AS mice. This is consistent with a recent study indicating that EEG abnormalities and seizures occur by P30 in AS mice (Mandel-Brehm et al., 2015), prior to the emergence of mIPSC and eIPSC deficits onto L2/3 pyramidal neurons (Wallace et al., 2012).

Intriguingly, GABAergic *Ube3a* deletion produces atypical accumulations of CCVs in presynaptic terminals (Figures 7A3 and




Figure 6. GABAergic *Ube3a* Loss Selectively Enhances LFP Spectral Power in the Delta Band

(A) Schematized configuration for LFP recordings in non-anesthetized mice.
(B) Sample V1 LFP recordings ([B₁], scale bar: 100 µV, 1 s) and quantification of average spectral power (B₂) from *Control* (n = 11) and *Ube3a^{FLOX/p+}::Gad2-Cre* (n = 11) mice at ~P100. (B₃) Quantification of the region (3 to 4 Hz) encompassing the largest genotypic difference in power within the delta band.
(C) Sample V1 LFP recordings ([C₁], scale bar: 100 µV, 1 s) and quantification of average spectral power (C₂) from *Control* (n = 12), *Ube3a^{STOP/p+}* (n = 9), and *Ube3a^{STOP/p+}::Gad2-Cre* (n = 11) mice at ~P100. (C₃) Quantification of the region (2 to 3 Hz) encompassing the largest genotypic difference in power within the delta band. Data represent mean ± SEM. *p ≤ 0.05.

7A4), despite failing to yield deficits in GABAergic synaptic recovery following high-frequency stimulation. Increased presynaptic CCVs are a hallmark of deficient clathrin-mediated endocytosis (Cremona et al., 1999; Luthi et al., 2001; Milosevic et al., 2011), though they could also possibly reflect compensation for impairments in clathrin-independent modes of synaptic vesicle recycling (Daly et al., 2000). Regardless of the underlying cause, accumulations of clathrin-coated endocytic profiles in the synapse typically predict electrophysiological impairments in synaptic depletion and recovery, especially within GABAergic interneurons that display high-frequency firing (Cremona et al., 1999; Luthi et al., 2001; Hayashi et al., 2008). Our electrical stimulation parameters might not have been optimized to reveal deficiencies in synaptic vesicle recycling, perhaps explaining the dissociation between this phenotype and GABAergic presynaptic CCV accumulations. More puzzling is the fact that selective GABAergic *Ube3a* loss led to CCV accumulations at glutamatergic synapses (Figure 7A5); unless *Ube3a* loss in GABAergic neurons triggers cell-nonautonomous defects in synaptic vesicle cycling, we would expect CCV phenotypes to be confined to GABAergic terminals. The parsimonious explanation is that CCV accumulations provide a readout of circuit hyperexcitability owed to GABAergic *Ube3a* loss, signaling the recent history of high-frequency activity at both GABAergic and glutamatergic presynaptic terminals. It remains to be elucidated how *Ube3a* loss impairs GABAergic synaptic recovery in AS mice, but our

data implicate a mechanism requiring loss of *Ube3a* in both glutamatergic and GABAergic neurons (Figures 1E3 and 2D3).

Implications of Defective Tonic GABAergic Inhibition in AS Mice

Here we show that glutamatergic *Ube3a* loss impairs the receipt of tonic GABAergic inhibition by L2/3 pyramidal neurons in the absence of EEG abnormalities and seizures (Figures 3G, 5B, and 6C), indicating a lack of relevance to the pathogenesis of hyperexcitability in AS. Considering the apparent cell-autonomous nature of this defect, it is reasonable to speculate that tonic GABAergic tone onto GABAergic neurons is also diminished in AS. However, such a deficit is equally unlikely to factor in the pathogenesis of hyperexcitability; GABAergic neuron-specific deletion of δ-GABA_{AR}s actually enhances phasic inhibition, thereby suppressing hippocampal network excitability and seizure susceptibility (Lee and Maguire, 2013). Nevertheless, decreases in tonic GABAergic neurotransmission have the potential to alter network dynamics throughout the brain (Brickley and Mody, 2012; Lee and Maguire, 2014) and may contribute to the manifestation of AS phenotypes besides epilepsy. For example, tonic inhibitory deficits onto cerebellar granule cells in AS mice are linked to impaired locomotion, which is amenable to rescue by the δ-GABA_{AR} superagonist THIP (Gaboxadol) (Egawa et al., 2012). It has since been shown that cerebellar deficits consequent to the loss of tonic GABAergic inhibition onto




Figure 7. GABAergic *Ube3a* Loss Underlies Presynaptic CCV Accumulation at Both GABAergic and Glutamatergic Synapses

(A) Electron micrographs of dendritic inhibitory synapses stained for GABA in *Control* (**A₁**) and *Ube3a*^{FLOX/p+::Gad2-Cre} (**A₂**) mice at ~P80. Green denotes GABAergic axon terminal, blue denotes dendrite, inset highlights clathrin-coated vesicles (CCVs) (scale bar: 200 nm). Average CCV densities at dendritic GABAergic synapses ([**A₃**], *Control* n = 89 synapses from 3 mice; *Ube3a*^{FLOX/p+::Gad2-Cre} n = 77 synapses from three mice), somatic GABAergic synapses ([**A₄**], *Control* n = 78 synapses from three mice; *Ube3a*^{FLOX/p+::Gad2-Cre} n = 81 synapses from three mice), and spinous glutamatergic synapses ([**A₅**], *Control* n = 82 synapses from three mice; *Ube3a*^{FLOX/p+::Gad2-Cre} n = 80 synapses from three mice).

(B) Electron micrographs of dendritic inhibitory synapses stained for GABA in *Control* (**B₁**), *Ube3a*^{STOP/p+} (**B₂**), and *Ube3a*^{STOP/p+::Gad2-Cre} (**B₃**) mice at ~P80. Green denotes GABAergic axon terminal, blue denotes dendrite, inset highlights CCVs (scale bar: 400 nm). Average CCV densities at dendritic GABAergic synapses ([**B₄**], *Control* n = 110 synapses from three mice; *Ube3a*^{STOP/p+} n = 119 synapses from three mice; *Ube3a*^{STOP/p+::Gad2-Cre} n = 115 synapses from three mice), somatic GABAergic synapses (**B₅**), *Control* n = 103 synapses from three mice; *Ube3a*^{STOP/p+} n = 114 synapses from three mice; *Ube3a*^{STOP/p+::Gad2-Cre} n = 110 synapses from three mice), and spinous glutamatergic synapses (**B₆**), *Control* n = 108 synapses from three mice; *Ube3a*^{STOP/p+} n = 113 synapses from three mice; *Ube3a*^{STOP/p+::Gad2-Cre} n = 113 synapses from three mice). Data represent mean ± SEM. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.0001.

cerebellar granule cells are clearly dissociable from locomotor defects (Bruinsma et al., 2015), suggesting that any therapeutic benefit of THIP for gross motor dysfunction works through the enhancement of tonic GABAergic inhibition in extracerebellar circuits. Together with our present findings, these studies underscore the need for further preclinical elucidation of a complex relationship between deficits in tonic inhibition and AS-like phenotypes; such knowledge will be essential to inform future clinical trials of THIP administration in AS patients—especially with regard to the selection of appropriate clinical endpoints.

Insights into Circuit-Level Consequences of GABAergic *Ube3a* Loss

What are the physiological mechanisms by which GABAergic *Ube3a* loss contributes to circuit imbalance? We previously found that neocortical fast-spiking interneurons receive normal excitatory synaptic drive and display appropriate intrinsic excit-

ability in the absence of *Ube3a* (Wallace et al., 2012), and our present studies indicate that a loss of GABAergic inhibition onto L2/3 pyramidal neurons is not involved in mediating circuit hyperexcitability (Figures 1, 4, 5, 6, and 7). These findings highlight the importance of moving beyond the L2/3 neocortical microcircuit to elucidate the physiological consequences of GABAergic *Ube3a* loss. While this is a vast parameter space, potentially involving numerous GABAergic neuron populations, our EEG findings point to a major role for the thalamic reticular nucleus (TRN). GABAergic TRN neurons directly regulate the oscillatory activity of thalamocortical circuits and, when activated, are capable of mediating selective enhancements of neocortical EEG power in the delta band (Zhang et al., 2009; Lewis et al., 2015)—the same power band in which we observed the majority of EEG power enhancement following GABAergic *Ube3a* loss. Indeed, pathological synchrony of TRN neurons has been implicated in the generation of delta frequency spike-wave oscillations and atypical absence seizures (Steriade, 2005; Huguenard and McCormick, 2007), both of which are commonly observed in AS (Vendrame et al., 2012; Thibert et al., 2013). High-amplitude

theta rhythmicity (4–6 Hz) with spiking is another common background EEG abnormality in AS (Thibert et al., 2013). Although this theta abnormality is most prominent in occipital regions, it seems to disappear by adolescence (Laan et al., 1997), perhaps explaining why we did not record significant enhancements in theta power in adult *Ube3a*^{STOP/p+} or *Ube3a*^{FLXO/p+::Gad2-Cre} mice, despite recording from V1 (Figure 6). Future work in AS models should focus on factors known to affect TRN neuron excitability and synchrony—including relative levels of excitatory and inhibitory synaptic drive, the integrity of gap junctions (Proulx et al., 2006; Lee et al., 2014), the expression of T-type calcium channels (Tsakiridou et al., 1995; Zhang et al., 2009), and cholinergic input (McCormick and Prince, 1986; Sun et al., 2013). However, intracortical GABAergic mechanisms that underlie pathological spike-wave discharges also remain of interest, especially those that engage disinhibitory circuitry (Pi et al., 2013; Hall et al., 2015).

Numerous GABAergic circuits outside the thalamus and cortex could also contribute to the enhancements in seizure susceptibility that we observed following GABAergic *Ube3a* loss. This might even be expected, considering the variety of seizure types known to occur in individuals with AS (Galván-Manso et al., 2005; Thibert et al., 2013). GABAergic circuits in the temporal lobe, hypothalamus, and striatum are all potentially of interest, but they have yet to be formally investigated. We have also yet to explore the possibility that GABAergic *Ube3a* loss mediates AS-like phenotypes other than EEG abnormalities and seizures. Recent findings suggest that GABAergic *Mecp2* loss precipitates the majority of Rett syndrome-like phenotypes in mice (Chao et al., 2010; Ito-Ishida et al., 2015). Considering the high degree of phenotypic overlap between AS and Rett syndrome (Jedele, 2007; Tan et al., 2014), this might foreshadow a similarly broad penetrance of AS-like phenotypes following GABAergic *Ube3a* loss. On the other hand, there is clearly divergence in the developmental mechanisms underlying AS and Rett syndrome, as indicated by studies modeling the temporal requirements for *Ube3a* and *Mecp2* gene reinstatement therapy, respectively (Guy et al., 2007; Silva-Santos et al., 2015).

Neuron-Type-Specific Strategies for the Treatment of Circuit Hyperexcitability in AS

Ube3a^{STOP/p+::Gad2-Cre} mice dually serve to model the effects of glutamatergic *Ube3a* loss as well as the therapeutic value of GABAergic *Ube3a* reinstatement. The lack of EEG abnormalities, seizures, and associated CCV accumulations in this line (Figures 5, 6, and 7) demonstrates the promise that GABAergic neuron-specific treatments hold for the treatment of hyperexcitability phenotypes in AS. However, this promise has its limits. Modeling of pan-cellular *Ube3a* reinstatement in *Ube3a*^{STOP/p+} mice predicts closure of a critical period for the amelioration of hyperexcitability phenotypes very early during postnatal development (Silva-Santos et al., 2015). Furthermore, GABAergic neuron-specific therapeutic approaches in AS are unlikely to involve the reinstatement of *UBE3A* expression. The only tractable target for the reinstatement of *UBE3A* expression in individuals with AS is the paternal *UBE3A* allele. Paternal *UBE3A* is intact, but epigenetically silenced in *cis* by a long non-coding RNA that includes a 3' *UBE3A*-antisense (*UBE3A*-ATS) sequence (Rougeulle et al.,

1998; Martins-Taylor et al., 2014). Thus far, successful preclinical efforts to unsilence paternal *Ube3a* have depended directly (Meng et al., 2015) or indirectly (Huang et al., 2012) on the down-regulation of *Ube3a*-ATS, which appears to be uniformly expressed by glutamatergic and GABAergic neurons. Therefore, signaling pathways that functionally intersect with UBE3A are more likely to provide neuron-type-specific targets for the development of AS therapeutics.

As a proof of concept, genetic normalization of calcium/calmodulin-dependent kinase type 2- α subunit (CaMKII- α) inhibitory hyperphosphorylation—a signaling deficit which decreases CaMKII enzymatic activity in *Ube3a*^{m-/p+} mice (Weeber et al., 2003)—rescues seizure phenotypes (van Woerden et al., 2007). Moreover, genetic reduction of the immediate-early gene, *Arc* (*Arc*^{+/-}), whose expression UBE3A may regulate either transcriptionally or posttranslationally through ubiquitination (Greer et al., 2010; Kühnle et al., 2013), normalizes EEG and abnormal responses to audiogenic stimuli in *Ube3a*^{m-/p+} mice (Mandel-Brehm et al., 2015). *Arc* expression is preferentially induced in CaMKII- α -expressing neurons in response to convulsive seizures (Vazdarjanova et al., 2006), indicating that the restoration of circuit balance in *Ube3a*^{m-/p+::Arc}^{+/-} mice may also be mediated by these cells. This poses a puzzle, however, considering our compelling evidence that GABAergic, but not glutamatergic, *Ube3a* loss drives the pathogenesis of hyperexcitability; in most brain regions including the cortex and hippocampus, CaMKII- α expression is restricted to glutamatergic neurons (Benson et al., 1992). An exception is the striatum in which CaMKII- α activity and *Arc* expression are readily induced within GABAergic spiny projection neurons in response to a variety of stimuli (Tan et al., 2000; Choe and Wang, 2002; Vazdarjanova et al., 2006; Anderson et al., 2008). GABAergic spiny projection neurons may thus be a nexus for seizure susceptibility or seizure resistance as mediated by loss or reinstatement of *Ube3a*, respectively. Alternatively, normalization of CaMKII- α and ARC function may work intrinsically through glutamatergic circuits to dampen their excitability and restore circuit balance, countering inhibitory deficits mediated by GABAergic *Ube3a* loss.

In summary, the present data compel us to revisit, reevaluate, and refine our previous hypotheses regarding the pathogenesis of circuit hyperexcitability in AS. We now appreciate that GABAergic *UBE3A* loss is likely to be the principal pathogenic factor underlying circuit hyperexcitability in the disorder; accordingly, the restoration of GABAergic neuronal function represents the most direct therapeutic strategy for the prevention or reversal of EEG abnormalities and seizures, provided the intervention occurs sufficiently early in development. This conceptual advance should help to focus future studies of the molecular mechanisms working both upstream and downstream of UBE3A within GABAergic neurons, perhaps yielding novel, actionable therapeutic targets.

EXPERIMENTAL PROCEDURES

See *Supplemental Experimental Procedures* for experimental details relating to mouse lines, AAV-Cre injections, electrophysiology, fluoroethyl-induced seizure assays, audiogenic seizure assays, qRT-PCR, western blotting, immunohistochemistry, and statistical analyses.

Animals

We raised all mice on a 12:12 light:dark cycle with ad libitum access to food and water. We used both male and female littermates at equivalent genotypic ratios and in strict compliance with animal protocols approved by the Institutional Animal Care and Use Committees of the University of North Carolina at Chapel Hill.

Electrophysiology

Whole-Cell Voltage-Clamp Recordings

We placed coronal slices containing V1 (see [Supplemental Experimental Procedures](#)) in a submersion chamber maintained at 30°C and perfused at 2 ml/min with oxygenated ACSF (in mM: 124 NaCl, 3 KCl, 1.25 NaH₂PO₄, 26 NaHCO₃, 1 MgCl₂, 2 CaCl₂, and 20 dextrose). We pulled patch pipettes from thick-walled borosilicate glass using a P2000 laser puller (Sutter Instruments). Open tip resistances were between 2–5 MΩ when pipettes were filled with the internal solution containing (in mM) 100 CsCH₃SO₃, 15 CsCl, 2.5 MgCl₂, 5 QX-314-Cl, 5 tetra-Cs-BAPTA, 10 HEPES, 4 Mg-ATP, 0.3 Na-GTP, and 0.025 Alexa-594, with pH adjusted to 7.25 and osmolarity adjusted to ~295 mOsm with sucrose.

We visually targeted L2/3 pyramidal neurons for recording using an Axio Examiner microscope (Zeiss, Germany) equipped with infrared differential interference contrast and epifluorescence optics. For successfully patched neurons, we achieved pipette seal resistances >1 GΩ, minimizing pipette capacitive transients prior to breakthrough. We performed voltage-clamp recordings in the whole-cell configuration using a Multiclamp 700B amplifier (Molecular Devices) with 10 kHz digitization and a 2 kHz low-pass Bessel filter. We acquired and analyzed data using pCLAMP 10 software (Molecular Devices, RRID:SCR_011323). We monitored changes in series and input resistance throughout each experiment by giving test step of −5 mV every 30 s and measuring the resultant amplitude of the capacitive current. We discarded neurons if series resistance surpassed 25 MΩ or if series resistance or input resistance changed by >25% during the course of an experiment. We confirmed L2/3 pyramidal neuronal identity by analyzing characteristic membrane properties ([Table S1](#)) and the presence of dendritic spines and prominent apical dendrites visualized with Alexa-594 dye.

In Vivo LFP Recordings

We backcrossed mice used for LFP and audiogenic seizure experiments (see [Supplemental Experimental Procedures](#)) six to seven generations onto the 129S2/SvPasCrl background, which is permissive for hyperexcitability phenotypes. For surgeries, we anesthetized adult mice (P75–118 on day 1 of recording) via intraperitoneal injections of ketamine (40 mg/kg) and xylazine (10 mg/kg), with 0.25% bupivacaine injected under the scalp for local analgesia. We then bilaterally implanted tungsten microelectrodes (FHC) in layer 4 of V1 (3.2–3.3 mm lateral to Lambda, 0.47 mm depth) and placed a silver wire in prefrontal cortex as a reference electrode. In order to enable head fixation during recordings, we attached a steel headpost to the skull anterior to bregma. We used dental cement to secure all elements in place and create a protective head cap.

We allowed mice to recover for at least 2 days following surgery before habituating them to the recording apparatus over 2 consecutive days. We acquired LFP data over the next 3 consecutive days. We head-fixed mice during all recording sessions (both habituation and LFP), orienting them toward a full-field gray screen for 15 min in a dark, quiet environment. We amplified LFP recordings 1,000× using single-channel amplifiers (Grass Technologies) with 0.1 Hz low-pass and 100 Hz high-pass filtration preceding acquisition and digitization at 4 kHz using Spike2 software (CED Ltd., RRID: SCR_000903). We analyzed spectral power using a fast Fourier transform resulting in bin sizes of 0.5 Hz. Prior to analysis, we manually excluded rarely occurring electrical artifacts corresponding to mouse movement. For each animal, we averaged power spectra from both hemispheres across all 3 days of recording.

Statistics

We performed all experiments and analyses blind to genotype. We performed all statistical analyses using GraphPad Prism 6 software (GraphPad Software Inc., RRID: SCR_002798).

SUPPLEMENTAL INFORMATION

Supplemental Information includes eight figures, one table, and Supplemental Experimental Procedures and can be found with this article online at <http://dx.doi.org/10.1016/j.neuron.2016.02.040>.

AUTHOR CONTRIBUTIONS

M.C.J. generated and molecularly characterized *Ube3a*^{FLOX} mice and designed and performed light microscopy, whole-cell electrophysiology, and behavioral seizure experiments. M.L.W. designed and performed whole-cell electrophysiology and audiogenic seizure experiments. M.S.S. designed and performed *in vivo* electrophysiology experiments. A.C.B. designed and performed electron microscopy experiments. B.G. designed and performed fluroethyl seizure experiments. G.M.v.W. advised on *Ube3a*^{STOP/+} experiments. I.F.K. performed qRT-PCR experiments. J.E.H. performed light microscopic analyses. M.J.Z. advised on qRT-PCR experiments. Y.E. advised on *Ube3a*^{STOP/+} experiments. R.J.W. designed experiments. B.D.P. designed experiments. M.C.J., M.L.W., R.J.W., and B.P. wrote the manuscript, which was edited by all co-authors.

CONFLICTS OF INTEREST

The authors declare that they have no competing financial interests.

ACKNOWLEDGMENTS

We thank Rylan Larsen and Janet Berrios for critical readings of the manuscript, Hyojin Kim for maintaining animal colonies, Kristen Phend for histological support, Dale Cowley and George Altshuller at the UNC Animal Models Core, William D. Snider for providing AAV-Cre virus, and Klaus-Armin Nave for providing *NEX-Cre* mice. This work was supported by NRSA fellowships 5F32NS077686 (to M.C.J.) and 1F31NS077847 (to M.L.W.), an NRSA institutional postdoctoral training grant T32-HD40127 (to M.S.S.), the Angelman Syndrome Foundation's Joseph E. Wagstaff fellowship (to I.F.K.), Angelman Syndrome Foundation grants (to Y.E. and B.D.P.), Simons Foundation SFARI Awards 274426 (to B.D.P.) and 275234 (to Y.E.), a Netherlands Organization for Scientific Research grant-ZonMW (to Y.E.), a Hersenstichting grant (to G.M.v.W.), NIMH 5R01MH093372 (to M.J.Z. and B.D.P.), NINDS 5R01NS039444 (to R.J.W.), and NINDS 1R01NS085093 (to B.D.P.). Confocal imaging was supported by NINDS Center Grant P30 NS045892 and NICHD Center Grant P30 HD03110. NIH grants to Velocigene at Regeneron Inc. (U01HG004085), the CSD Consortium (U01HG004080), and the KOMP Repository at UC Davis and CHORI (U42RR024244) funded the generation, curation, and distribution of the targeting vector used to produce *Ube3a*^{FLOX} mice.

Received: March 19, 2015

Revised: January 17, 2016

Accepted: February 24, 2016

Published: March 24, 2016

REFERENCES

- Anderson, S.M., Famous, K.R., Sadri-Vakili, G., Kumaresan, V., Schmidt, H.D., Bass, C.E., Terwilliger, E.F., Cha, J.H., and Pierce, R.C. (2008). CaMKII: a biochemical bridge linking accumbens dopamine and glutamate systems in cocaine seeking. *Nat. Neurosci.* 11, 344–353.
- Benson, D.L., Isackson, P.J., Gall, C.M., and Jones, E.G. (1992). Contrasting patterns in the localization of glutamic acid decarboxylase and Ca²⁺/calmodulin protein kinase gene expression in the rat central nervous system. *Neuroscience* 46, 825–849.
- Brickley, S.G., and Mody, I. (2012). Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. *Neuron* 73, 23–34.
- Bruinsma, C.F., Schonewille, M., Gao, Z., Aronica, E.M., Judson, M.C., Philpot, B.D., Hoebeek, F.E., van Woerden, G.M., De Zeeuw, C.I., and

- Elgersma, Y. (2015). Dissociation of locomotor and cerebellar deficits in a murine Angelman syndrome model. *J. Clin. Invest.* 125, 4305–4315.
- Buzsáki, G., Anastassiou, C.A., and Koch, C. (2012). The origin of extracellular fields and currents—EEG, ECoG, LFP and spikes. *Nat. Rev. Neurosci.* 13, 407–420.
- Chao, H.T., Chen, H., Samaco, R.C., Xue, M., Chahrour, M., Yoo, J., Neul, J.L., Gong, S., Lu, H.C., Heintz, N., et al. (2010). Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. *Nature* 468, 263–269.
- Choe, E.S., and Wang, J.Q. (2002). CaMKII regulates amphetamine-induced ERK1/2 phosphorylation in striatal neurons. *Neuroreport* 13, 1013–1016.
- Cooper, E.M., Hudson, A.W., Amos, J., Wagstaff, J., and Howley, P.M. (2004). Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein. *J. Biol. Chem.* 279, 41208–41217.
- Coulter, D.A., and Carlson, G.C. (2007). Functional regulation of the dentate gyrus by GABA-mediated inhibition. *Prog. Brain Res.* 163, 235–243.
- Cremona, O., Di Paolo, G., Wenk, M.R., Lüthi, A., Kim, W.T., Takei, K., Daniell, L., Nemoto, Y., Shears, S.B., Flavell, R.A., et al. (1999). Essential role of phosphoinositide metabolism in synaptic vesicle recycling. *Cell* 99, 179–188.
- Daly, C., Sugimori, M., Moreira, J.E., Ziff, E.B., and Llinás, R. (2000). Synaptophysin regulates clathrin-independent endocytosis of synaptic vesicles. *Proc. Natl. Acad. Sci. USA* 97, 6120–6125.
- Dibbens, L.M., Feng, H.J., Richards, M.C., Harkin, L.A., Hodgson, B.L., Scott, D., Jenkins, M., Petrou, S., Sutherland, G.R., Scheffer, I.E., et al. (2004). GABRD encoding a protein for extra- or peri-synaptic GABA_A receptors is a susceptibility locus for generalized epilepsies. *Hum. Mol. Genet.* 13, 1315–1319.
- Egawa, K., Kitagawa, K., Inoue, K., Takayama, M., Takayama, C., Saitoh, S., Kishino, T., Kitagawa, M., and Fukuda, A. (2012). Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome. *Sci. Transl. Med.* 4, 163Ra157.
- Galván-Manso, M., Campistol, J., Conill, J., and Sanmartí, F.X. (2005). Analysis of the characteristics of epilepsy in 37 patients with the molecular diagnosis of Angelman syndrome. *Epileptic Disord.* 7, 19–25.
- Goebels, S., Bormuth, I., Bode, U., Hermanson, O., Schwab, M.H., and Nave, K.A. (2006). Genetic targeting of principal neurons in neocortex and hippocampus of NEX-Cre mice. *Genesis* 44, 611–621.
- Greer, P.L., Hanayama, R., Bloodgood, B.L., Mardinly, A.R., Lipton, D.M., Flavell, S.W., Kim, T.K., Griffith, E.C., Waldon, Z., Maehr, R., et al. (2010). The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. *Cell* 140, 704–716.
- Guy, J., Gan, J., Selfridge, J., Cobb, S., and Bird, A. (2007). Reversal of neurological defects in a mouse model of Rett syndrome. *Science* 315, 1143–1147.
- Hall, S., Hunt, M., Simon, A., Cunningham, L.G., Carracedo, L.M., Schofield, I.S., Forsyth, R., Traub, R.D., and Whittington, M.A. (2015). Unbalanced Peptidergic Inhibition in Superficial Neocortex Underlies Spike and Wave Seizure Activity. *J. Neurosci.* 35, 9302–9314.
- Hayashi, M., Raimondi, A., O'Toole, E., Paradise, S., Collesi, C., Cremona, O., Ferguson, S.M., and De Camilli, P. (2008). Cell- and stimulus-dependent heterogeneity of synaptic vesicle endocytic recycling mechanisms revealed by studies of dynamin 1-null neurons. *Proc. Natl. Acad. Sci. USA* 105, 2175–2180.
- Hsu, D. (2007). The dentate gyrus as a filter or gate: a look back and a look ahead. *Prog. Brain Res.* 163, 601–613.
- Huang, H.S., Allen, J.A., Mabb, A.M., King, I.F., Miriyala, J., Taylor-Blake, B., Sciaky, N., Dutton, J.W., Jr., Lee, H.M., Chen, X., et al. (2012). Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. *Nature* 481, 185–189.
- Huguenard, J.R., and McCormick, D.A. (2007). Thalamic synchrony and dynamic regulation of global forebrain oscillations. *Trends Neurosci.* 30, 350–356.
- Ito-Ishida, A., Ure, K., Chen, H., Swann, J.W., and Zoghbi, H.Y. (2015). Loss of MeCP2 in Parvalbumin-and Somatostatin-Expressing Neurons in Mice Leads to Distinct Rett Syndrome-like Phenotypes. *Neuron* 88, 651–658.
- Jedele, K.B. (2007). The overlapping spectrum of Rett and Angelman syndromes: a clinical review. *Semin. Pediatr. Neurol.* 14, 108–117.
- Jiang, Y.H., Armstrong, D., Albrecht, U., Atkins, C.M., Noebels, J.L., Eichele, G., Sweatt, J.D., and Beaudet, A.L. (1998). Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. *Neuron* 21, 799–811.
- Judson, M.C., Sosa-Pagan, J.O., Del Cid, W.A., Han, J.E., and Philpot, B.D. (2014). Allelic specificity of Ube3a expression in the mouse brain during postnatal development. *J. Comp. Neurol.* 522, 1874–1896.
- Kadiyala, S.B., Papandrea, D., Herron, B.J., and Ferland, R.J. (2014). Segregation of seizure traits in C57 black mouse substrains using the repeated-fluroethyl model. *PLoS ONE* 9, e90506.
- Kishino, T., Lalande, M., and Wagstaff, J. (1997). UBE3A/E6-AP mutations cause Angelman syndrome. *Nat. Genet.* 15, 70–73.
- Krasowski, M.D. (2000). Differential modulatory actions of the volatile convulsant fluroethyl and its anesthetic isomer at inhibitory ligand-gated ion channels. *Neuropharmacology* 39, 1168–1183.
- Kühnle, S., Mothes, B., Matentzoglu, K., and Scheffner, M. (2013). Role of the ubiquitin ligase E6AP/UBE3A in controlling levels of the synaptic protein Arc. *Proc. Natl. Acad. Sci. USA* 110, 8888–8893.
- Laan, L.A., Renier, W.O., Arts, W.F., Buntinx, I.M., vd Burgt, I.J., Stroink, H., Beuten, J., Zwijnderman, K.H., van Dijk, J.G., and Brouwer, O.F. (1997). Evolution of epilepsy and EEG findings in Angelman syndrome. *Epilepsia* 38, 195–199.
- Lee, V., and Maguire, J. (2013). Impact of inhibitory constraint of interneurons on neuronal excitability. *J. Neurophysiol.* 110, 2520–2535.
- Lee, V., and Maguire, J. (2014). The impact of tonic GABA_A receptor-mediated inhibition on neuronal excitability varies across brain region and cell type. *Front. Neural Circuits* 8, 3.
- Lee, S.C., Patrick, S.L., Richardson, K.A., and Connors, B.W. (2014). Two functionally distinct networks of gap junction-coupled inhibitory neurons in the thalamic reticular nucleus. *J. Neurosci.* 34, 13170–13182.
- Lewis, L.D., Voigts, J., Flores, F.J., Schmitt, L.I., Wilson, M.A., Halassa, M.M., and Brown, E.N. (2015). Thalamic reticular nucleus induces fast and local modulation of arousal state. *eLife* 4, e08760.
- Lüthi, A., Di Paolo, G., Cremona, O., Daniell, L., De Camilli, P., and McCormick, D.A. (2001). Synaptotagmin 1 contributes to maintaining the stability of GABAergic transmission in primary cultures of cortical neurons. *J. Neurosci.* 21, 9101–9111.
- Mabb, A.M., and Ehlers, M.D. (2010). Ubiquitination in postsynaptic function and plasticity. *Annu. Rev. Cell Dev. Biol.* 26, 179–210.
- Mabb, A.M., Judson, M.C., Zylka, M.J., and Philpot, B.D. (2011). Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. *Trends Neurosci.* 34, 293–303.
- Maguire, J.L., Stell, B.M., Rafizadeh, M., and Mody, I. (2005). Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety. *Nat. Neurosci.* 8, 797–804.
- Mandel-Brehm, C., Salogiannis, J., Dhamne, S.C., Rotenberg, A., and Greenberg, M.E. (2015). Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression. *Proc. Natl. Acad. Sci. USA* 112, 5129–5134.
- Martins-Taylor, K., Hsiao, J.S., Chen, P.F., Glatt-Deeley, H., De Smith, A.J., Blakemore, A.I., Lalande, M., and Chamberlain, S.J. (2014). Imprinted expression of UBE3A in non-neuronal cells from a Prader-Willi syndrome patient with an atypical deletion. *Hum. Mol. Genet.* 23, 2364–2373.
- Matsuura, T., Sutcliffe, J.S., Fang, P., Galjaard, R.J., Jiang, Y.H., Benton, C.S., Rommens, J.M., and Beaudet, A.L. (1997). De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. *Nat. Genet.* 15, 74–77.
- McCormick, D.A., and Prince, D.A. (1986). Acetylcholine induces burst firing in thalamic reticular neurones by activating a potassium conductance. *Nature* 319, 402–405.

- Meng, L., Ward, A.J., Chun, S., Bennett, C.F., Beaudet, A.L., and Rigo, F. (2015). Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. *Nature* 518, 409–412.
- Milosevic, I., Giovedi, S., Lou, X., Raimondi, A., Collesi, C., Shen, H., Paradise, S., O'Toole, E., Ferguson, S., Cremona, O., and De Camilli, P. (2011). Recruitment of endophilin to clathrin-coated pit necks is required for efficient vesicle uncoating after fission. *Neuron* 72, 587–601.
- Nieto, M., Monuki, E.S., Tang, H., Imitola, J., Haubst, N., Khoury, S.J., Cunningham, J., Gotz, M., and Walsh, C.A. (2004). Expression of Cux-1 and Cux-2 in the subventricular zone and upper layers II-IV of the cerebral cortex. *J. Comp. Neurol.* 479, 168–180.
- Pi, H.J., Hangya, B., Kvitsiani, D., Sanders, J.I., Huang, Z.J., and Kepcs, A. (2013). Cortical interneurons that specialize in disinhibitory control. *Nature* 503, 521–524.
- Proulx, E., Leshchenko, Y., Kokarovtseva, L., Khokhotva, V., El-Beheiry, M., Snead, O.C., 3rd, and Perez Velazquez, J.L. (2006). Functional contribution of specific brain areas to absence seizures: role of thalamic gap-junctional coupling. *Eur. J. Neurosci.* 23, 489–496.
- Pun, R.Y., Rolle, I.J., Lasarge, C.L., Hosford, B.E., Rosen, J.M., Uhl, J.D., Schmeltzer, S.N., Faulkner, C., Bronson, S.L., Murphy, B.L., et al. (2012). Excessive activation of mTOR in postnatally generated granule cells is sufficient to cause epilepsy. *Neuron* 75, 1022–1034.
- Rotin, D., and Kumar, S. (2009). Physiological functions of the HECT family of ubiquitin ligases. *Nat. Rev. Mol. Cell Biol.* 10, 398–409.
- Rougeulle, C., Glatt, H., and Lalande, M. (1997). The Angelman syndrome candidate gene, UBE3A/E6-AP, is imprinted in brain. *Nat. Genet.* 17, 14–15.
- Rougeulle, C., Cardoso, C., Fontés, M., Colleaux, L., and Lalande, M. (1998). An imprinted antisense RNA overlaps UBE3A and a second maternally expressed transcript. *Nat. Genet.* 19, 15–16.
- Silva-Santos, S., van Woerden, G.M., Bruinsma, C.F., Mientjes, E., Jolfaei, M.A., Distel, B., Kushner, S.A., and Elgersma, Y. (2015). Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. *J. Clin. Invest.* 125, 2069–2076.
- Spigelman, I., Li, Z., Banerjee, P.K., Mihalek, R.M., Homanics, G.E., and Olsen, R.W. (2002). Behavior and physiology of mice lacking the GABA α -receptor delta subunit. *Epilepsia* 43 (Suppl 5), 3–8.
- Steriade, M. (2005). Sleep, epilepsy and thalamic reticular inhibitory neurons. *Trends Neurosci.* 28, 317–324.
- Sun, Y.G., Pita-Almenar, J.D., Wu, C.S., Renger, J.J., Uebel, V.N., Lu, H.C., and Beierlein, M. (2013). Biphasic cholinergic synaptic transmission controls action potential activity in thalamic reticular nucleus neurons. *J. Neurosci.* 33, 2048–2059.
- Sutcliffe, J.S., Jiang, Y.H., Galjaard, R.J., Matsuura, T., Fang, P., Kubota, T., Christian, S.L., Bressler, J., Cattanach, B., Ledbetter, D.H., and Beaudet, A.L. (1997). The E6-AP ubiquitin-protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region. *Genome Res.* 7, 368–377.
- Tan, A., Moratalla, R., Lyford, G.L., Worley, P., and Graybiel, A.M. (2000). The activity-regulated cytoskeletal-associated protein arc is expressed in different striosome-matrix patterns following exposure to amphetamine and cocaine. *J. Neurochem.* 74, 2074–2078.
- Tan, W.H., Bird, L.M., Thibert, R.L., and Williams, C.A. (2014). If not Angelman, what is it? A review of Angelman-like syndromes. *Am. J. Med. Genet. A.* 164A, 975–992.
- Taniguchi, H., He, M., Wu, P., Kim, S., Paik, R., Sugino, K., Kvitsiani, D., Fu, Y., Lu, J., Lin, Y., et al. (2011). A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. *Neuron* 71, 995–1013.
- Thibert, R.L., Larson, A.M., Hsieh, D.T., Raby, A.R., and Thiele, E.A. (2013). Neurologic manifestations of Angelman syndrome. *Pediatr. Neurol.* 48, 271–279.
- Tsakiridou, E., Bertollini, L., de Curtis, M., Avanzini, G., and Pape, H.C. (1995). Selective increase in T-type calcium conductance of reticular thalamic neurons in a rat model of absence epilepsy. *J. Neurosci.* 15, 3110–3117.
- van Woerden, G.M., Harris, K.D., Hojati, M.R., Gustin, R.M., Qiu, S., de Avila Freire, R., Jiang, Y.H., Elgersma, Y., and Weeber, E.J. (2007). Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation. *Nat. Neurosci.* 10, 280–282.
- Vazdarjanova, A., Ramirez-Amaya, V., Insel, N., Plummer, T.K., Rosi, S., Chowdhury, S., Mikhael, D., Worley, P.F., Guzowski, J.F., and Barnes, C.A. (2006). Spatial exploration induces ARC, a plasticity-related immediate-early gene, only in calcium/calmodulin-dependent protein kinase II-positive principal excitatory and inhibitory neurons of the rat forebrain. *J. Comp. Neurol.* 498, 317–329.
- Vendrame, M., Loddenkemper, T., Zarowski, M., Gregas, M., Shuhaiher, H., Sarco, D.P., Morales, A., Nespeca, M., Sharpe, C., Haas, K., et al. (2012). Analysis of EEG patterns and genotypes in patients with Angelman syndrome. *Epilepsy Behav.* 23, 261–265.
- Wallace, M.L., Burette, A.C., Weinberg, R.J., and Philpot, B.D. (2012). Maternal loss of Ube3a produces an excitatory/inhibitory imbalance through neuron type-specific synaptic defects. *Neuron* 74, 793–800.
- Weeber, E.J., Jiang, Y.H., Elgersma, Y., Varga, A.W., Carrasquillo, Y., Brown, S.E., Christian, J.M., Mirnikoo, B., Silva, A., Beaudet, A.L., and Sweatt, J.D. (2003). Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. *J. Neurosci.* 23, 2634–2644.
- Wei, W., Zhang, N., Peng, Z., Houser, C.R., and Mody, I. (2003). Perisynaptic localization of delta subunit-containing GABA(A) receptors and their activation by GABA spillover in the mouse dentate gyrus. *J. Neurosci.* 23, 10650–10661.
- Williams, C.A., Beaudet, A.L., Clayton-Smith, J., Knoll, J.H., Kyllerman, M., Laan, L.A., Magenis, R.E., Moncla, A., Schinzel, A.A., Summers, J.A., and Wagstaff, J. (2006). Angelman syndrome 2005: updated consensus for diagnostic criteria. *Am. J. Med. Genet. A.* 140, 413–418.
- Yamasaki, K., Joh, K., Ohta, T., Masuzaki, H., Ishimaru, T., Mukai, T., Niikawa, N., Ogawa, M., Wagstaff, J., and Kishino, T. (2003). Neurons but not glial cells show reciprocal imprinting of sense and antisense transcripts of Ube3a. *Hum. Mol. Genet.* 12, 837–847.
- Zhang, Y., Llinás, R.R., and Lisman, J.E. (2009). Inhibition of NMDARs in the Nucleus Reticularis of the Thalamus Produces Delta Frequency Bursting. *Front. Neural Circuits* 3, 20.